Drug Profile
Enavogliflozin - Daewoong
Alternative Names: Dapagliflozin; DWP-16001; DWP16001 drug A; DWP16001 drug B; DWP16001 drug C; Envlo; ODP 9401Latest Information Update: 06 Dec 2023
Price :
$50
*
At a glance
- Originator Daewoong Pharmaceutical
- Class Antihypercalcaemics; Antihyperglycaemics; Benzofurans; Cyclopropanes; Heart failure therapies; Small molecules
- Mechanism of Action Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
- Phase III Heart failure
Most Recent Events
- 04 Dec 2023 m8 Pharmaceuticals has been acquired by Acino
- 27 Nov 2023 Daewoong Pharmaceutical plans a phase III trial in Type 2 diabetes mellitus (In adults, In the elderly) (PO, Tablet) in December 2023 (NCT06141980)
- 01 Nov 2023 Launched for Type 2 diabetes mellitus (Combination therapy, In the elderly, In adults) in South Korea prior to November 2023 (PO)